Literature DB >> 1504072

Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity.

W R Perkins1, S R Minchey, L T Boni, C E Swenson, M C Popescu, R F Pasternack, A S Janoff.   

Abstract

When interacting with phospholipid in an aqueous environment, amphotericin B forms unusual structures of markedly reduced toxicity (Janoff et al. (1988) Proc. Natl. Acad. Sci. USA 85, 6122-6126). These structures, which appear ribbon-like by freeze-fracture electron microscopy (EM), are found exclusively at amphotericin B to lipid mole ratios of 1:3 to 1:1. At lower mole ratios they occur in combination with liposomes. Circular dichroism (CD) spectra revealed two distinct modes of lipid-amphotericin B interaction, one for liposomes and one for the ribbon-like structures. In isolated liposomes, amphotericin B which comprised 3-4 mole percent of the bulk lipid was monomeric and exhibited a hemolytic activity comparable to amphotericin B suspended in deoxycholate. Above 3-4 mole percent amphotericin B, ribbon-like structures emerged and CD spectra indicated drug-lipid complexation. Minimal inhibitory concentrations for Candida albicans of liposomal and complexed amphotericin B were comparable and could be attributed to amphotericin a release as a result of lipid breakdown within the ribbon-like material by a heat labile extracellular yeast product (lipase). Negative stain EM of the ribbon-like structures indicated that the ribbon-like appearance seen by freeze-fracture EM arises as a consequence of the cross-fracturing of what are aggregated, collapsed single lamellar, presumably interdigitated, membranes. Studies examining complexation of amphotericin B with either DMPC or DMPG demonstrated that headgroup interactions played little role in the formation of the ribbon-like structures. With these results we propose that ribbon-like structures result from phase separation of amphotericin B-phospholipid complexes within the phospholipid matrix such that amphotericin B release, and thus acute toxicity, is curtailed. Formation of amphotericin B-lipid structures such as those described here indicates a possible new role for lipid as a stabilizing matrix for drug delivery of lipophilic substances, specifically where a highly ordered packing arrangement between lipid and compound can be achieved.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1504072     DOI: 10.1016/0005-2736(92)90414-h

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  16 in total

1.  In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important?

Authors:  C E Swenson; W R Perkins; P Roberts; I Ahmad; R Stevens; D A Stevens; A S Janoff
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.

Authors:  T J Walsh; P Whitcomb; S Piscitelli; W D Figg; S Hill; S J Chanock; P Jarosinski; R Gupta; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

3.  Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2.

Authors:  Raymund R Razonable; Martin Henault; Linda N Lee; Carmen Laethem; Paul A Johnston; Harold L Watson; Carlos V Paya
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats.

Authors:  R Bhamra; A Sa'ad; L E Bolcsak; A S Janoff; C E Swenson
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 5.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

6.  Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.

Authors:  T J Walsh; V Yeldandi; M McEvoy; C Gonzalez; S Chanock; A Freifeld; N I Seibel; P O Whitcomb; P Jarosinski; G Boswell; I Bekersky; A Alak; D Buell; J Barret; W Wilson
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 7.  Biopharmaceutical aspects of lipid formulations of amphotericin B.

Authors:  G Storm; E van Etten
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

Review 8.  Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential.

Authors:  G Gregoriadis; A T Florence
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

9.  Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B.

Authors:  K M Wasan; M G Rosenblum; L Cheung; G Lopez-Berestein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

10.  Amphotericin B incorporated into egg lecithin-bile salt mixed micelles: molecular and cellular aspects relevant to therapeutic efficacy in experimental mycoses.

Authors:  J Brajtburg; S Elberg; G S Kobayashi; J Bolard
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.